BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc * Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study…















